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Following genetic immunization of laying ducks with a plasmid expressing
Helicobacter pylori UreB (large subunit of urease), IgY against UreB were obtained
from egg yolks. These polyclonal and monospecific IgY antibodies are of higher-titer
and specifically recognize recombinant H. pylori urease purified from Escherichia
coli. To our knowledge this is the first report describing generation of IgY antibodies
directed against antigens of H. pylori by DNA-based immunization.
Helicobacter pylori is a Gram-negative, spi-
ral, microaerophylic bacterium that infects
the stomach of more than 50% of the human
population worldwide. It is associated with
gastritis, peptic ulcer and gastric cancer and
it has been classified as a category 1 carcino-
gen by WHO (Ruggiero et al., 2002; Prinz et
al., 2003). Several existing detection methods
such as Western blots or ELISA are useful to
identify antibodies against H. pylori in blood,
saliva or urine of the infected individuals.
Other tests consist of the revealing of the
urease activity (urea breath test) or detection
of H. pylori antigens in biopsies or stools. Cur-
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rent therapies are not effective in 100% and
fail due to antibiotic resistance. No effective
vaccine against H. pylori exists, although sev-
eral vaccine candidates including an oral
whole-cell vaccine (Helivax, Antex Biologi-
cals) and an intramuscular trivalent acellular
vaccine (Chiron Vaccines) have been tested in
clinical trials (for a recent review: Ruggiero et
al., 2002). Antibodies directed against spe-
cific H. pylori targets could be used either for
diagnosis or as therapeutic agents.
Only few recent reports exist about genera-
tion of antibodies against H. pylori antigens.
These reports include monoclonal antibodies
isolated from an immune phage display li-
brary constructed from peripheral blood lym-
phocytes of infected patients (Reiche et al.,
2002), bovine colostral antibodies isolated
from colostrums of cows immunized with
killed H. pylori bacteria (Casswall et al., 2002;
Marnila et al., 2003) and chicken yolk-derived
antibodies obtained, as in the previous case,
against the whole-cell lysate of H. pylori
(Shimamoto et al., 2002; Shin et al., 2002;
2003). The results achieved by the above au-
thors suggest that passive immunization
upon oral administration of antibodies can be
effective. Urease is the major antigen of H.
pylori that is essential for bacteria to survive
within the acidic environment of the stomach.
Effective blocking of urease activity seems to
be a good strategy to prevent colonization of
the stomach by H. pylori. Significant research
efforts concerning vaccine development con-
centrate around this protein, including our at-
tempts to obtain effective production of UreB
in plant tissues (Brodzik et al., 2000a; 2000b).
An interesting observation is that antibodies
raised against entire urease do not neutralize
its enzymatic activity; however, even in such
a case their protective potential has been
shown (Blanchard et al., 1995). Monoclonal
antibodies capable not only of binding but
also of inhibiting H. pylori urease have been
identified and shown to recognize a short
linear epitope (Hirota et al., 2001).
In the present study we took advantage of a
novel approach of “DNA designed” egg yolk
antibody production by DNA immunization of
ducks (Rollier et al., 2000). As these authors
described, following genetic immunization of
breeding ducks with a plasmid encoding a
given antigen, specific and biologically active
IgY antibodies are transmitted vertically
from their serum into the egg and accumulate
in egg yolk from which they can be extracted
and purified.
The aim of this work was to use the above
approach for generation and preliminary
characterization of polyclonal, monospecific
antibodies against the catalytic subunit
(UreB) of H. pylori urease.
MATERIALS AND METHODS
DNA manipulation. All manipulations
were performed according to standard tech-
niques (Sambrook et al., 1989). The ureB gene
of H. pylori was amplified using the oligo-
nucleotides UREBPCI1 (5 gcgaattccgccatg-
gaaaagatta 3) and UREBPCI2 (5 gcgctcta-
gactagaaaatgctaaag 3) as primers, and pAR3
(Brodzik et al., 2000a) as a template. The
1.7-kb DNA fragment was cloned into the
NcoI and XbaI sites of pCI vector (Promega).
The resulting plasmid pAR72 was purified
from DH5 using commercial plasmid purifi-
cation systems (Qiagen).
Immunization of ducks. Immunization of
ducks was performed in animal facilities of
INSERM U271 (Lyon, France) with a total of
500 g of plasmid DNA per animal by intra-
muscular injection in multiple sites, followed
by two subsequent boosts (Rollier et al.,
2000). Eggs collection and IgY purification
from the eggs were performed as previously
described (Rollier et al., 2000).
Dot-blot. Aliquots of 0.5 l of partially puri-
fied recombinant antigens of H. pylori or bo-
vine serum albumin (BSA) were spotted on
Nylon membranes. Each dot contained ap-
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proximately 125 ng of protein. The spots were
allowed to dry and the membranes were
blocked for 1 h in phosphate-buffered saline
(PBS) with 5% skim milk, incubated for 1 h
with IgY diluted to 10 g/ml, washed (3  10
min) and incubated with anti-duck-IgG, AP
conjugated (Kirkegaard & Perry Laborato-
ries) used as secondary antibodies (5000 fold
diluted, 1 h). After four washes of 5 min each
in PBS the NBT/BCIP detection system (Pro-
mega) was applied.
ELISA. Ninety-six-well ELISA plates
(EIA/RIA high binding, Costar) were coated
O/N with 0.5 g of either recombinant UreB
protein purified from Escherichia coli or BSA
in 100 l of PBS. The coating was followed by
60-min incubation with the tested IgY anti-
bodies (dilutions 1 :500 to 1 :16000 were
used), 5-min washing in PBS, 60-min blocking
with 0.5% BSA in PBS and 60-min incubation
with secondary antibodies (goat derived
anti-duck- IgG, HRP conjugated, Kirkegaard
& Perry Laboratories). For the detection TMB
Peroxidase EIA Substrate Kit (BioRad) was
used and absorbance was determined at ei-
ther 655 nm (reactions not stopped) or at
450 nm (reactions stopped with 2 M sulfuric
acid).
Preparing E. coli extract containing ac-
tive recombinant urease of H. pylori.
Crude protein extract containing active H.
pylori urease was prepared from E. coli strain
transformed with two plasmids: pHP902 and
pHP808 (Hu & Mobley, 1993), harboring
ureAB and the cluster of genes (ureCD ureAB
ureIEFGH), respectively. As a negative con-
trol served a protein extract prepared from
E. coli transformed with pHP902 and pAC-
YC184. The bacteria were grown (until A600
reached 0.8–1.2) in minimal M9 medium
(Sambrook et al., 1989) supplemented with
glucose (0.4%), tryptophan (20 mg/l), NiCl2 (1
M), and ampicillin (100 g/ml) and chloram-
phenicol (30 g/ml) as selection markers. Al-
ternatively, LB medium (Sambrook et al.,
1989) with ampicillin and chloramphenicol as
above additionally supplemented with
700 M NiCl2 was used for extract prepara-
tion. Bacterial cells were centrifuged, sus-
pended in 0.1 vol. of 20 mM sodium phos-
phate buffer, pH 6.8, and sonicated (6  10 s
at 40% Duty Cycle, 5th level Output Control,
on ice. Model 250 Sonifier, Branson Ultra-
sonics Corporation). The supernatant ob-
tained after centrifugation (10000  g, 10
min, 4oC) was treated as a crude extract for
urease activity assays.
Urease activity assay. The final volume of
the reaction was always 1 ml. Each sample
contained 2.6 l of 1 M Na2HPO4, 6.5 l of
1 M KH2PO4 and 10 l of enzyme extract. Re-
action was started by addition of 50 l of
4.16 M urea and incubated for 15 min at
37oC. For testing of the neutralizing activi-
ties, antibodies were added before urea and
incubated with the enzymatic extract for 10
or 30 min. Then, urea was added and incuba-
tion continued as above. Aliquots of 100 l
were taken and added to the freshly prepared
mixture containing 500 l of solution A (1%
phenol, 0.05% sodium nitroprusside) and
500 l of solution B (0.5% NaOH and 0.05%
NaOCl). A650 was read after 5 min at 37
oC. A
control extract without active urease was
used as a negative control. The activity of
urease is presented as the difference in
absorbance at 650 nm between the extracts
containing active urease and the control ex-
tracts that were identically treated.
Cultures of H. pylori. A strain of H. pylori
(CagA+ VacA+ urease+ catalase+) previously
isolated from the stomach of an infected pa-
tient and stored at –80oC was used for verifi-
cation of the neutralizing potential of the
tested IgY. For the solid media test, antibod-
ies were spotted on small filter discs, placed
on plates (Columbia with 5% Horse Blood,
BioMerieux) containing the bacteria spread
and incubated for 48 h at 37oC in an atmo-
sphere with 5% CO2. For the liquid culture
tests, bacteria were grown in Brucella Broth
(Becton Dickinson) supplemented with fetal
bovine serum in the presence or absence of
antibodies.
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RESULTS AND DISCUSSION
UreB-specific IgY antibodies can be ob-
tained from eggs of ducks immunized with
plasmid DNA expressing ureB of H. pylori
Plasmid pAR72, containing H. pylori ureB
gene was used for DNA immunization of two
ducks. Eggs were collected and large amounts
of IgY antibodies (about 50 mg/egg) were pu-
rified from their yolks. Preliminary character-
ization of the obtained IgY using dot-blot tech-
nique indicated that IgY from one of the im-
munized ducks (No. J435) specifically recog-
nized partially purified recombinant H. pylori
UreB (Fig. 1). The same antibodies bound nei-
ther recombinant H. pylori HspB nor BSA,
both used as controls. In addition, IgY puri-
fied from eggs of another duck (duck No.
J511), which was immunized with a plasmid
expressing hspB of H. pylori and which has
not mounted a specific anti-HspB response,
were used as an additional negative control.
The IgY from the duck No. J511 were not able
to detect any of the three proteins tested
(Fig. 1).
Detailed characterization of IgY specificity
was performed by ELISA. The IgY from duck
No. J435 specifically recognized UreB in this
test. Importantly, the titer of these IgY was
high since a 8000-fold dilution was still able to
recognize UreB (Fig. 2).
UreB-specific IgYs do not have neutralizing
properties nor inhibit growth of H. pylori
Bacterial extracts containing catalytically
active recombinant H. pylori urease were pre-
pared from E. coli cells co-transformed with
two plasmids: pHP902 encoding two subunits
of H. pylori urease and pHP808 containing
not only the structural genes for H. pylori
urease (ureAB) but also genes necessary for
production of catalytically active urease,
which encode accessory proteins involved in
incorporation of nickel into the active center
of the enzyme (Hu & Mobley, 1993). IgY from
ducks No. J435 and J511 were tested for their
ability to inhibit the activity of H. pylori
urease. The lack of influence of preincubation
of the bacterial extract with anti-UreB IgY an-
tibodies from duck or with polyclonal
anti-urease IgG antibodies from rabbit (not
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Figure 1. Dot-blot experiment with IgY antibod-
ies purified from eggs of duck immunized with
plasmid pAR72 (J435) and a control duck (J511).
Positions of partially purified proteins is marked in
the box; H, recombinant H. pylori HspB purified from
E. coli cells; U, recombinant H. pylori UreB purified
from E. coli cells; B, bovine serum albumin (BSA) from
commercial source.
Figure 2. Specific activities of anti-UreB IgY anti-
bodies tested in ELISA experiments.
IgY antibodies were purified from eggs obtained either
from duck No. J435 (immunized with pAR72 plasmid)
or from duck No. J511 (control). Dilutions of stock
preparations of IgY indicated below were tested in trip-
licates for their ability to recognize either BSA or re-
combinant H. pylori UreB used to coat the ELISA
plates: 1, 1:500; 2, 1:1000; 3, 1:2000; 4, 1:4000; 5,
1:8000. C, denotes the control (buffer without any anti-
bodies).
shown) on the urease activity clearly demon-
strated the absence of any neutralizing activ-
ity of the tested immunoglobulins. This is not
surprising since such activity is detected only
rarely when antibodies are raised against en-
tire UreB protein (Thomas et al., 1992). Most
anti-UreB antibodies with urease-inhibiting
activity were raised against well-defined short
epitopes of UreB protein (Hirota et al., 2001;
Houimel et al., 2001). Additional experiments
performed with bacterial cells grown either
on solid media or in liquid cultures failed to
demonstrate any influence of IgY on growth
parameters of the tested H. pylori strain (not
shown).
In summary, highly specific anti-UreB IgY
antibodies were generated by genetic immu-
nization of ducks with a plasmid encoding the
entire UreB protein. Similarly to the rabbit
antibodies raised against the entire UreB, the
obtained IgY antibodies were not neutralizing
in vitro, although this does not exclude the
possibility that these antibodies might be pro-
tective in vivo (Blanchard et al., 1995).
Whether genetic immunization of ducks with
plasmids encoding selected UreB epitopes
may generate neutralizing and protective
anti-UreB IgY antibodies is not known and
warrants further studies.
The anti-UreB IgY antibodies obtained by us
using this new approach of “DNA-designed”
antibody production in egg yolk may be of
particular value for diagnostic purpose due
to: (i) large yield of IgY generated in the “egg
yolk factory”; (ii) non invasive production of
such antibodies; (iii) no need of purified pro-
tein for immunization; (iv) high affinity of an-
tibodies; (v) absence of cross reactivity with
mammalian immunoglobulins and comple-
ment.
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